VENBIO PARTNERS LLC
Q1 2022 Form 13-F
SAN FRANCISCO, CALIFORNIA
CIK 0001776382
· CRD 290045
· Exempt reporting adviser
$451.1M Reported Value Total
Exempt Reporting Adviser
WWW.VENBIO.COM
Source: Form ADV filed 2026-03-12
Reported value
$451.1M
Quarter over quarter
-14.5%
Holdings
10
Top-10 concentration
100.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
David Pezeshki
Chief Financial Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2022 13F record
Q1 2022 13F filing summary
| Period of report | March 31, 2022 |
|---|---|
| Filed | May 16, 2022 |
| Form | 13F-HR |
| Reported value | $451.1M |
| Positions | 10 |
| Change in reported value | -18.7% |
| New positions | 1 |
| Exited positions | 0 |
| Position turnover | 10.0% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
7 | $519.4M |
|
Q1 2026 13F
Filed May 15, 2026
|
6 | $280.6M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
6 | $216.3M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
6 | $176.4M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
6 | $114.8M |
|
Q1 2025 13F
Filed May 15, 2025
|
7 | $123.6M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
7 | $170.7M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
6 | $194.3M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
6 | $231.5M |
|
Q1 2024 13F
Filed May 15, 2024
|
5 | $281.9M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
7 | $667.2M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
8 | $352.7M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
7 | $276.3M |
|
Q1 2023 13F
Filed May 15, 2023
|
6 | $180.4M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
7 | $322.5M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
8 | $432.2M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
9 | $351.2M |
|
Q1 2022 13F
Filed May 16, 2022
|
10 | $451.1M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
9 | $555.1M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
9 | $1.0B |
11 earlier quarters on file — choose one from the quarter menu above.
Top 10 holdings · Q1 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ALXO ALX ONCOLOGY HLDGS INC | $163.9M | 36.34% |
| 2 | HRMY HARMONY BIOSCIENCES HLDGS IN | $75.1M | 16.66% |
| 3 | VTYX VENTYX BIOSCIENCES INC | $68.0M | 15.08% |
| 4 | PHVS PHARVARIS N V | $41.8M | 9.26% |
| 5 | CINC CINCOR PHARMA INC | $34.7M | 7.7% |
| 6 | AKRO AKERO THERAPEUTICS INC | $30.8M | 6.83% |
| 7 | IMPL IMPEL NEUROPHARMA INC | $17.6M | 3.9% |
| 8 | CMPI CHECKMATE PHARMACEUTICALS IN | $11.7M | 2.6% |
| 9 | ELEV ELEVATION ONCOLOGY INC | $6.6M | 1.46% |
| 10 | VRNA VERONA PHARMA PLC | $808.0K | 0.18% |
Values as reported on the Q1 2022 Form 13F. Every position is in the holdings table below.